ENDRA Life Sciences (NDRA) Retained Earnings (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Retained Earnings for 11 consecutive years, with $118.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings rose 10.1% year-over-year to $118.0 million in Q2 2026; TTM through Jun 2026 was $118.0 million, a 10.1% increase from a year earlier, with the FY2025 full-year figure at $112.7 million, up 6.35% from the prior year.
• Retained Earnings was $118.0 million for Q2 2026 at ENDRA Life Sciences, up from $113.6 million in the prior quarter.
• Over five years, Retained Earnings peaked at $118.0 million in Q2 2026 and troughed at $80.6 million in Q1 2022.
• A 5-year average of $100.3 million and a median of $102.1 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings rose 13.65% in 2022 and climbed 1.18% in 2025, its largest moves.
• Over 5 years, Retained Earnings stood at $89.1 million in 2022, then advanced by 9.56% to $97.6 million in 2023, then rose by 8.62% to $106.0 million in 2024, then advanced by 6.35% to $112.7 million in 2025, then grew by 4.68% to $118.0 million in 2026.
• The last three Retained Earnings figures came in at $118.0 million (Q2 2026), $113.6 million (Q1 2026), and $112.7 million (Q4 2025), per Business Quant data.